NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
Clinical Trials
11 trialsNCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT04249947 2025-02-17
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Phase 1 Terminated
NCT04918810 2024-11-22
GUIDE
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Terminated
NCT04844749 2024-02-05
VERACITY
Veru Inc.
Phase 3 Terminated
NCT04404140 2023-10-17
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
Phase 1 Terminated
NCT04116164 2023-09-25
Safety and Targeting of Anti-hk2 Antibody in mCRPC
SpectronRX
Phase EARLY_PHASE1 Terminated
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT02057666 2021-04-23
TasQ003
Ipsen
Phase 3 Terminated